Literature DB >> 21051918

FOXP3+ regulatory T cells and tumoral indoleamine 2,3-dioxygenase expression predicts the carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas.

Noritoshi Kobayashi1, Kensuke Kubota, Shingo Kato, Seitaro Watanabe, Takeshi Shimamura, Hiroyuki Kirikoshi, Satoru Saito, Michio Ueda, Itaru Endo, Yoshiaki Inayama, Shin Maeda, Atsushi Nakajima.   

Abstract

BACKGROUND AND AIMS: FOXP3+ regulatory T cells (Tregs) play a central role in self-tolerance and suppress the effective antitumor immune response. A recent study revealed that indoleamine 2,3-dioxygenase (IDO)-mediated tryptophan depletion was able to affect local tumor-infiltrating lymphocytes. The aim of this study was to investigate the clinical significance of the tumor-infiltrating Tregs and tumoral IDO expression during the progression of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas.
METHODS: We investigated the prevalence and localization of FOXP3+ Tregs, CD8+ lymphocytes, and IDO expression in IPMNs by immunohistochemistry. We recruited 39 cases with IPMNs (IPMA: adenoma, n = 11; IPMB: borderline malignancy, n = 9; IPMC: noninvasive carcinoma, n = 7; I-IPMC: invasive IPMC, n = 12).
RESULTS: The prevalence of Tregs increased step by step during the carcinogenesis of IPMNs (Kruskal-Wallis test: p < 0.0001). IDO expression in the tumor was observed in 5 cases with IPMNs (IPMC, n = 1; I-IPMC, n = 4). IDO expression in the tumor was positively correlated with the prevalence of Tregs in IPMNs.
CONCLUSIONS: FOXP3+ Tregs play a role in controlling the immune surveillance against IPMNs at the premalignant stage. IDO expression in the tumor is one of the late-stage phenomena of multistage carcinogenesis of IPMNs.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21051918     DOI: 10.1159/000308966

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  12 in total

Review 1.  Immune Therapy in GI Malignancies: A Review.

Authors:  Judy Wang; Kim A Reiss; Rina Khatri; Elizabeth Jaffee; Dan Laheru
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

Review 2.  Process of hepatic metastasis from pancreatic cancer: biology with clinical significance.

Authors:  Haojun Shi; Ji Li; Deliang Fu
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-07       Impact factor: 4.553

3.  Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer.

Authors:  Lars Plassmeier; Richard Knoop; Jens Waldmann; Rebecca Kesselring; Malte Buchholz; Stefan Fichtner-Feigl; Detlef K Bartsch; Volker Fendrich
Journal:  Langenbecks Arch Surg       Date:  2013-08-30       Impact factor: 3.445

4.  Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy.

Authors:  Mathilde Feist; Zhi Zhu; Enyong Dai; Congrong Ma; Zuqiang Liu; Esther Giehl; Roshni Ravindranathan; Stacy J Kowalsky; Natasa Obermajer; Udai S Kammula; Andrew J H Lee; Michael T Lotze; Zong Sheng Guo; David L Bartlett
Journal:  Cancer Gene Ther       Date:  2020-07-07       Impact factor: 5.987

5.  Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer.

Authors:  Ben C Creelan; Scott Antonia; Gerold Bepler; Timothy J Garrett; George R Simon; Hatem H Soliman
Journal:  Oncoimmunology       Date:  2013-03-01       Impact factor: 8.110

6.  The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy.

Authors:  Hirokazu Shoji; Kohei Tada; Shigehisa Kitano; Takashi Nishimura; Yasuhiro Shimada; Kengo Nagashima; Kazunori Aoki; Nobuyoshi Hiraoka; Yoshitaka Honma; Satoru Iwasa; Atsuo Takashima; Ken Kato; Narikazu Boku; Kazufumi Honda; Tesshi Yamada; Yuji Heike; Tetsuya Hamaguchi
Journal:  Oncotarget       Date:  2017-05-30

7.  Prognostic impact of the tumor-infiltrating regulatory T-cell (Foxp3+)/activated cytotoxic T lymphocyte (granzyme B+) ratio on resected left-sided pancreatic cancer.

Authors:  Ho Kyoung Hwang; Hyoung-Il Kim; Se Hoon Kim; Junjeong Choi; Chang Moo Kang; Kyung Sik Kim; Woo Jung Lee
Journal:  Oncol Lett       Date:  2016-10-13       Impact factor: 2.967

8.  FOXP3 and CEACAM6 expression and T cell infiltration in the occurrence and development of colon cancer.

Authors:  Yingying Liu; Tingting Xia; Chunhui Jin; Dongmei Gu; Jie Yu; Weiqiang Shi; K E Zhang; Liping Zhang; Jianxin Ye; Ling Li
Journal:  Oncol Lett       Date:  2016-04-14       Impact factor: 2.967

Review 9.  Role of immune cells in pancreatic cancer from bench to clinical application: An updated review.

Authors:  Jae Hyuck Chang; Yongjian Jiang; Venu G Pillarisetty
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

Review 10.  T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer?

Authors:  Qi Zhou; Xufeng Tao; Shilin Xia; Fangyue Guo; Chen Pan; Hong Xiang; Dong Shang
Journal:  Front Oncol       Date:  2020-03-24       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.